CoreCap Advisors LLC Purchases 200 Shares of Glaukos Co. (NYSE:GKOS)

CoreCap Advisors LLC raised its holdings in Glaukos Co. (NYSE:GKOS) by 36.4% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 750 shares of the medical instruments supplier’s stock after buying an additional 200 shares during the quarter. CoreCap Advisors LLC’s holdings in Glaukos were worth $112,000 as of its most recent SEC filing.

A number of other hedge funds also recently made changes to their positions in the business. IFP Advisors Inc acquired a new position in Glaukos in the fourth quarter worth about $43,000. Asset Planning Inc acquired a new position in shares of Glaukos in the 4th quarter worth approximately $90,000. Picton Mahoney Asset Management bought a new position in shares of Glaukos during the 4th quarter worth approximately $125,000. SBI Securities Co. Ltd. acquired a new stake in Glaukos in the 4th quarter valued at $153,000. Finally, Smartleaf Asset Management LLC grew its position in Glaukos by 275.4% in the fourth quarter. Smartleaf Asset Management LLC now owns 1,100 shares of the medical instruments supplier’s stock valued at $164,000 after acquiring an additional 807 shares during the period. Institutional investors and hedge funds own 99.04% of the company’s stock.

Insider Buying and Selling at Glaukos

In other Glaukos news, insider Tomas Navratil sold 3,416 shares of the business’s stock in a transaction that occurred on Friday, February 14th. The stock was sold at an average price of $147.14, for a total transaction of $502,630.24. Following the transaction, the insider now owns 72,437 shares of the company’s stock, valued at $10,658,380.18. The trade was a 4.50% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Alex R. Thurman sold 1,520 shares of the stock in a transaction that occurred on Tuesday, March 25th. The stock was sold at an average price of $106.84, for a total value of $162,396.80. Following the transaction, the chief financial officer now owns 53,431 shares in the company, valued at approximately $5,708,568.04. This trade represents a 2.77% decrease in their position. The disclosure for this sale can be found here. Insiders own 5.80% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on the stock. Mizuho lowered their target price on shares of Glaukos from $200.00 to $175.00 and set an “outperform” rating on the stock in a report on Wednesday, April 16th. Needham & Company LLC reduced their target price on Glaukos from $176.00 to $115.00 and set a “buy” rating on the stock in a report on Thursday, May 1st. Wells Fargo & Company downgraded Glaukos from an “overweight” rating to an “equal weight” rating and cut their price objective for the company from $160.00 to $86.00 in a research report on Thursday, May 1st. Truist Financial restated a “buy” rating and set a $135.00 target price (down previously from $140.00) on shares of Glaukos in a report on Thursday, May 1st. Finally, Piper Sandler cut their price target on Glaukos from $180.00 to $165.00 and set an “overweight” rating for the company in a report on Tuesday, April 15th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and ten have assigned a buy rating to the stock. Based on data from MarketBeat.com, Glaukos presently has a consensus rating of “Moderate Buy” and an average price target of $134.67.

Glaukos Stock Performance

Glaukos stock opened at $94.57 on Tuesday. The company has a market cap of $5.40 billion, a PE ratio of -32.95 and a beta of 0.83. The company has a current ratio of 5.54, a quick ratio of 4.71 and a debt-to-equity ratio of 0.19. Glaukos Co. has a 1 year low of $77.10 and a 1 year high of $163.71. The company’s 50-day moving average is $94.52 and its two-hundred day moving average is $127.06.

Glaukos (NYSE:GKOS) last released its quarterly earnings data on Wednesday, April 30th. The medical instruments supplier reported ($0.22) EPS for the quarter, beating analysts’ consensus estimates of ($0.33) by $0.11. Glaukos had a negative return on equity of 16.53% and a negative net margin of 39.04%. The business had revenue of $106.66 million during the quarter, compared to the consensus estimate of $102.78 million. During the same quarter in the prior year, the company posted ($0.70) earnings per share. The firm’s revenue was up 24.6% on a year-over-year basis. Equities analysts anticipate that Glaukos Co. will post -1.08 earnings per share for the current year.

Glaukos Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.